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ABSTRACT 
 
 
TITLE OF THE ABSTRACT : To asses the Diagnostic validity of Procacitonin in Burns  
      Sepsis patients. 
 
DEPARTMENT   :Plastic and Reconstructive surgery 
NAME OF THE CANDIDATE :Dr. Naveen Kumar H R 
DEGREE AND SUBJECT  :Mch , Plastic surgery 
NAME OF THE GUIDE  :Dr. Kingsly Paul M 
 
AIM / OBJECTIVE: 
 
To asses the Diagnostic validity of Procacitonin in Burns Sepsis patients. 
 
MATERIAL AND METHODS: 
  
 This was a prospective diagnostic study done for a period of 9 months involving 36 cases 
who sustained > 20% TBSA of second degree burns. The criteria explained by the American 
Burn Association (ABA – 2007) were used as the reference standard to diagnose sepsis. Patients 
were continuously monitored for the development of signs and symptoms of sepsis. 
Procalcitonin (PCT) estimation was done at the time of sepsis and without sepsis. The values of 
PCT correlate with the sepsis parameters of American Burn Association. Data was analysed 
using Receiver operating curve analysis, Fisher exact test, t test, Mann whitney U test. 
 
RESULTS:  
 
The predictive ability of the PCT was determined by using the ROC (Receiver 
operating curve) and the area under the curve was calculated with 95% confidence 
intervals. Analysis of the coordinate points reveled the best threshold values of PCT for the 
prediction of sepsis based on the combination of sensitivity and specificity of each 
proposed threshold. The cut off value was 5ng/ml based on the ROC analysis at the 
sensitivity of 88.9% and specificity of 83.3% with area under the curve was 91%. 
CONCLUSION: 
 
 Procalcitonin has sensitivity of 88.9% and specificity of 83.3% in diagnosing sepsis in 
burns patients at the cut off value of 5 ng/ml.. 
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Introduction: 
 Sepsis is one of the major cause of mortality in burns patients.
1
 Sepsis is defined as 
systemic inflammatory response with documented infection. If not treated, then the 
infection will lead to organ dysfunction, hypoperfusion and hypotension called as severe 
sepsis. Later it will end up with septic shock. Systemic inflammatory response syndrome 
(SIRS) can be due to either infectious or non infectious cause. In major trauma and burns 
patients it is always difficult to differentiate whether SIRS is a result of injury itself or 
due to superimposed infection. Most of the clinical signs of infection such as fever, 
tachycardia , leucocytosis were also present in SIRS.  
 
 Thus to overcome this a consensus panel was formed by American burns 
association and guidelines were framed to define sepsis in burns patient. In this the 
definition of SIRS and severe sepsis was excluded and the range of vital parameters 
were raised, platelet count and patient glucose level included. Inability to feed the patient 
enterally for more than 24 hrs was also one of the criteria. To diagnose it as sepsis, 
infection should be documented or the infection should respond to the antibiotic started 
empirically. These guidelines were based on the consensus and not on any prospective 
clinical studies. 
 
 Clinically it is very important to identify systemic infection at the earliest of its 
stage to initiate antibiotic therapy and to prevent further mortality.
2
 Though blood 
culture is the gold standard to diagnose systemic infection it will take several days to get 
the growth of infecting organism and also the presence of negative culture doesn’t assure 
the absence of infection. So it is necessary to identify the indirect circulating markers of 
systemic infection that can be rapidly assessed and reliable. So many markers have been 
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explained in the literature eg., CRP – C reactive protein, TNF  , IL-6 etc. But Cytokine 
and non cytokine markers are not used routinely in burned patients. The marker that 
have been consistently elevated in patients with infection  is procalcitonin(PCT). Studies 
have shown that increased plasma levels of PCT are sensitive and specific marker of 
infection.
3
  
 
 The marker is more specific for the bacterial infection and increase several folds 
within 4 hrs of infection, reaches peak by 6 hrs and plateau by 8-24hrs, then return to 
baseline by 2-3 days. Its half life is 24-30hrs. These qualities of the marker made it 
clinically suitable and to repeat at regular intervals. 
 
In the past many studies had been done to assess the PCT value both in burns and 
non burns cases. Due to the localized infection the value of PCT may be raised 
marginally even in the absence of sepsis. So the cut off value considered in the previous 
studies has very low threshold for the diagnosis of sepsis. This study done to assess the 
PCT value in burns patients and also to find a cut off value to suspect sepsis at initial 
stages and include it as a protocol in our set up. 
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Aims and objective: 
 
1) To find the diagnostic validity (sensitivity and  specificity) of procalcitonin in burns 
sepsis  patients. 
2) To find a cut off value of procalcitonin to diagnose sepsis in burns patients. 
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Materials & Methods 
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Materials and methods :  
 This is a prospective study done for a period of 9 months from March 1
st
 , 2012 to 
November 31
st
 , 2012 in the Department of Plastic Surgery, Christian Medical College 
and Hospital, Vellore. This study was approved by the Institutional Review Board. There 
were 36 patients involved in this study. 
Inclusion criteria :   All patients with more than or equal to 20% burns. 
Exclusion criteria :     All patients with less than 20% burns. 
 
 All patients presented with 20% or more of burns admitted in the burns ward of 
CMC Hospital were included in the study. If the patient got admitted within 24 hr of 
injury the resuscitation protocol of our burns unit was started which involves  
- Admission to the burns unit.  
-  Insert a central line preferably in non burnt areas. 
- To place a Foleys catheter to measure urine output. 
- To start fluid (Ringer lactate) as per parkland formula. 
- Burn wound care and silver sulfadiazine dressing. 
- Insert naso gastric tube in major burns 
- I.V. morphine as analgesic round the clock. 
- To send all base line blood investigations. 
(Hemoglobin, Total and differential count, Random blood sugar, Creatinine, 
electrolytes). 
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 On the first day of resuscitation period we maintained a urine output of 30-
50ml/kg/hr. we titrated the fluid based on urine output. On second day of resuscitation 
colloid was started. We infused 0.5ml/kg/%burns of plasma with 5% dextrose to 
maintain urine output of 1ml/kg/hr. The Patients were monitored continuously. Every 4
th
 
hourly Temperature, pulse rate and respiratory rate were recorded daily from the day of 
admission. Patient daily calorie intake was documented. Twice a week baseline blood 
investigations were done. Pus culture of the wound, blood culture, urine culture and 
sputum culture were done from third day of burns depending on the patient condition. 
All the parameters necessary to diagnose burns sepsis according to American Burn 
Association (ABA) consensus were documented in a Chart to diagnose sepsis (Chart 
attached in Annexure 1). This was the reference standard of our study. 
 
American burn association consensus definition of sepsis and infection :  
  3 or more of the following :  
1. Temperature >39°C or <36.5°C 
2. Progressive tachycardia (> 110/min) 
3. Progressive tachypnoea (>25/min) 
4. Thrombocytopenia < 1 lac (only applies 3 days after initial resuscitation) 
5. Hyperglycemia (in the absence of pre-existing diabetes mellitus) 
6. Inability to continue enteral feeding >24 h. 
Plus documented infection with one or more of the following: 
1. Culture positive infection. 
2. Pathologic tissue source identified. 
3. Clinical response to antimicrobials. 
14 
 
 
 All patients presented with 20% or more of burns were included in the study. The 
Patients were monitored continuously for any signs and symptoms of sepsis after 
admission. The sepsis parameter was documented in a Chart daily and this will help the 
analyser to know exactly at what time period the patient was gone into sepsis. A base line 
PCT level estimation was done at the time of admission when the patient is not into 
sepsis. The next PCT level estimation was done when he/she fulfils the criteria of sepsis. 
So PCT was analysed approximately thrice for each patient, once at the time of 
admission, sepsis and when patient recovers from sepsis. By doing this each case was 
served as his/her own control. The collected data was divided into two groups, i.e.: values 
noted at the time of each pre and post sepsis episode. At the end of the study the data 
analyser was blind for the collected PCT value. He would be correlating the PCT value 
with the present sepsis parameter and to assess the diagnostic validity of the test. Those of 
the patients without an episode of sepsis had a single PCT assay reading at admission 
which was served as a baseline PCT estimation reading. All the other investigation are 
being done routinely according to our Burns Protocol. Temperature, Heart rate and 
Respiratory rate monitoring 4
th
 hrly. TC/DC, Platelet count, Random blood sugar - on day 
of admission and every 3rd day, Wound culture and Blood Culture – on 3rd post Burn Day 
Urine c/s and sputum c/s – depending on the septic foci .Investigation will be repeated 
frequently depending on the patient condition. 
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Procalcitonin estimation: 
  
 Procalcitonin measurement in our study was done using the test kits obtained from 
B.R.A.H.M.S (Kryptor method) Germany. The results were obtained within 19 min of 
the test. The analytical sensitivity of the test was 0.019ng/ml and the functional assay 
sensitivity of 0.06ng/ml with a probability of 95%. The Kryptor method consists of 
sheep polyclonal anti – calcitonin antibody and a monoclonal anti – katacalcin antibody 
which binds to the calcitonin precursor molecules. The antibodies used in this assay do 
not show cross reaction with human calcitonin (up to 2.5ng/ml) and katacalcin (up to 
10ng/ml) , human a-CGRP and b-CGRP (up to 4 mcg/ml). The interfering substances 
like icteric , haemolytic, hyperlipemic samples and also samples with turbid or contain 
fibrin if present then it is signalled by Kryptor.  
 
Measuring principle :  
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 The technology used was TRACE – time resolved amplified cryptate emission 
(Kryptor – PCT) based on non – radioactive transfer of energy which takes place from 
europium cryptate to XL 665 and this could only be possible when  PCT present in the 
sample are sandwiched between the antibodies forming Ag-Ab complex. The energy 
transferred or the intensity of the signal is proportional to the amount of PCT within the 
sample. These commercially available kits measures both PCT- I , PCT-II and the 
cleavage products of calcitonin precursor molecule which consists the residues of 
calcitonin and katacalcin.  
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Thesis : Review of literature 
 American College of Chest Physicians/Society of Critical Care Medicine  
(ACCP/SCCM) in 1992  described the Systemic  inflammatory response syndrome 
(SIRS) based on clinical and experimental results which is independent of cause.
4
  
According to this two or more following criteria should be fulfilled to diagnose as SIRS 
1. Temperature > 38 or < 36 degree 
2. Heart rate > 90/min. 
3. Respiratory rate > 20/min or Paco2 <32mmHg 
4. Leucocyte count >12000/<4000/>10% immature (band) forms.  
 The criteria explained were more sensitive and less specific. In order to improve 
the specificity there was a meeting regarding this issue in second conference in 2001. 
Additional criteria were added that defined metabolic, biochemical and functional 
alterations associated with SIRS. Those criteria were hyperglycemia, edema, elevated 
plasma C reactive protein, coagulation abnormalities, thrombocytopenia, 
hyperbilirubinemia and ileus.
5
 SIRS can occur in infective and non infective cases. For 
eg., in burns , multiple trauma, pancreatitis etc. sepsis was defined as SIRS with 
documented infection. 
 In 2002 the same consensus also explained the SIRS in children and severe sepsis 
was defined as sepsis with one of the organ dysfunction like cardiovascular system, 
ARDS or two or more of other organs dysfunction (respiratory, renal, neurologic, 
hepatic or hematologic) and Septic shock as Sepsis with arterial hypotension despite 
adequate fluid resuscitation. 
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 But the extensive wounds in burns patients had chronic exposure to inflammatory 
mediators which causes fever, tachycardia, tachypnea and resetting of baseline metabolic 
rate considered as the normal physiologic response. So in order to define sepsis in burns 
the SIRS category was dropped as this was considered as the protective response of the 
body towards exaggerated inflammatory condition. Thus in 2007 American Burn 
Association consensus conference  defined sepsis and infection in burns with the 
following guidelines.
6
  
SIRS: 
Not applicable in burn patients 
Sepsis: 
 3 or more of the following triggers search for infection 
1. Temperature >39°C or <36.5°C 
2. Progressive tachycardia (>110 /min) 
3. Progressive tachypnoea (> 25/min) 
4. Thrombocytopenia (only applies 3 days after initial resuscitation) 
5. Hyperglycemia (in the absence of preexisting diabetes mellitus) 
6. Inability to continue enteral feeding >24 hrs 
 
Plus documented infection with one or more of the following 
1. Culture positive infection 
2. Pathologic tissue source identified 
3. Clinical response to antimicrobials 
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Severe sepsis:  
Not applicable in burns patients 
Septic shock:  
Sepsis with persistent hypotension despite adequate fluid resuscitation. 
 The aim of this guidelines is to have a consistent diagnosis in all burn centres and 
to help in future research. Still the term SIRS is used to explain the pathogenesis of post 
burn injury and sepsis. SIRS is also called as hypermetabolic response in burn injury 
which is more meaningful. 
Two hit hypothesis of sepsis :  
 The pathophysiology of SIRS and sepsis was explained by Two hit hypothesis. 
The injured host manifest an exaggerated inflammatory response if exposed to secondary 
inflammatory stimulus during the post injury period. The initial insult resulted in 
production of lymphokine interferon alpha (IFN ) acts as first signal and prime 
macrophages for increased inflammatory response. A second stimulus causes the primed 
macrophages to secrete increase amount of TNF . This was not produced in large 
amount during the initial inflammatory insult. If the primed macrophages were exposed 
to even small amount of endotoxin at the time of second stimulus then TNF   was 
produced enormously.  T- lymphocytes also become hyper responsive at the post injury 
period.  
 Another mechanism of increased responsiveness by macrophages is ligand for Toll 
like receptors (TLR 2) and TLR 4 following burn injury.
7
 These are proteins which 
forms receptor complexes along with microbial products such as peptidoglycans, 
lipopolysaccharide and lipoproteins. This theory was also proved by many animal 
21 
 
studies by different authors. When a week old thermally injured sheep exposed to 
systemic bacterial challenge found increase pulmonary hypertension and hyperdynamic 
response.
8
 Also when combined administration of low dose endotoxin and TNF  in rat 
model resulted in hypotension and metabolic effects that was seen after giving highly 
lethal dose of each compound alone.
9
  
Inflammatory Mediators of SIRS :  
 The initial stimulus for the activation and release of inflammatory mediators of 
SIRS is either major injury or infection. The various mediators were mentioned in brief. 
 Cytokines:  have unique role in causing SIRS after injury.  The most important 
were TNF , IL 6, IL 1 and interferon (IFN ).  
 Extensive studies were done on TNF . This is released by activated macrophages 
soon after injury.
10
 The molecule has its effects both locally and systemically. At the site 
of burn injury it activates local immune response against antimicrobials and also helps in 
tissue repair. But systemically it has devastating effects causing tissue injury, organ 
dysfunction and finally death. The other systemic manifestations of TNF were induction 
of fever, stimulation to secrete acute phase proteins, coagulation cascade activation, 
myocardial depression,
 11
 systemic vasodilatation, hypotension, catabolism and 
hypoglycaemia. The most important effect of TNF  is its ability to induce apoptosis of 
various cell types that causes tissue injury when present in high concentration in 
systemic circulation.
12
 TNF  also stimulate the release of IL 1 and IL 6.   
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 IL 1 actions are similar to TNF  except it doesn’t induce tissue injury or 
apoptosis by itself instead it potentiates the injurious effects of TNF .
13
  
 The function of IL 6 is to induce production of acute phase proteins  and acts as 
growth and differentiation factor for B lymphocytes. It is produced by macrophages, 
endothelial cells and fibroblasts.  
 IFN  is the primary cytokine produced at the initial insult by T lymphocytes and 
NK cells in response to antigen presentation and induction from IL 12 and IL18. The 
primary functions of IFN   is to amplify inflammatory response of macrophages, induce 
secretion of inflammatory mediators (TNF , IL 1) and potentiates the antigen 
presentation by HLA II complex. The blockade of IFN   markedly decrease the 
inflammatory effects induced by the bacterial endotoxin.
14
  
Chemokines : 
 The other group of proteins responsible for SIRS is chemokines. Primarily they 
function as chemotactic factor for leucocytes. Among various chemokines which were 
described IL 8 is the potent chemoattractant for neutrophils and major factor in 
recruiting neutrophils to inflammatory foci. IL 8 also mediate tissue injury in lung in 
response to trauma and burns.
15
  
Non cytokine factors : also have role in the pathogenesis of SIRS they were platelet 
activating factor ( PAF) , Leucotrienes (LT) ,Thromboxane A2. 
PAF : This belongs to phospholipid family having a messenger function. It is released by 
endothelial cells, platelets, neutrophils  and regulates the release of cytokines. It also 
helps in adhesion of neutrophils to endothelial cells. It also causes changes in vascular 
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permeability and acts as chemotaxis of leukocytes. PAF can trigger inflammation, 
thrombosis and also mediate molecular and cellular interactions. 
Leukotriens (LT) : Synthesized from leucocytes and acts on G- protein coupled 
receptors. It causes contraction of endothelial cells and encourage capillary leakage thus 
sustaining the inflammatory response. 
(Thromboxane A2)TXA2 : It belongs to eicasanoids family, synthesized from platelets. 
It promotes platelet aggregation, vasoconstriction and tissue thrombosis. 
 
Systemic manifestations of the burns patients 
 
 This is divided in to early hypovolemic shock phase and delayed phase of systemic 
inflammation (SIRS) in which monocytes, macrophages and  T cells were activated to 
release various mediators of inflammation mainly cytokines. The activated T cells 
divided in to Th1 cells secrets proinflammatory cytokines and Th2 cells secrets anti 
inflammatory cytokines. The cytokines were differentiated from the hormones  in a way 
that these were not secreted by a specialized cells arranged in glandular tissue, it has 
broad spectrum of activity when compare to hormones and these were either positive or 
negative regulators of cell cycle, its differentiation, cell survival, apoptosis  and 
transformation. 
There are three important factors which determine the effects of SIRS in burns patients: 
1. Severity of initial SIRS is proportional to severity of injury. 
2. Prolonged SIRS leads to higher complication rate. 
3. Adaptive capacity of the host to SIRS. 
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 So lesser the initial insult lesser the SIRS. Prolongation of SIRS can be reduced by 
adequate fluid resuscitation, excision of necrotic tissue and enteral feeding. The 
inflammation is mediated by the cytokines which are released in response to mechanical, 
thermal and ischemia reperfusion injury at the cellular level. The proinflammatory 
mediators were TNF  and IL- 6. Worsening or prolongation of SIRS were due to 
inadequate fluid resuscitation, repeated insults by infection, tissue necrosis and 
endotoxin migration from the intestine. At the same time body responds by producing 
more anti inflammatory mediators. These were TGF  and IL 10. Producing excess of 
these anti inflammatory mediators will cause immunosupression and patient will 
exposed to uncontrollable infections. 
 Till  the early 90s the cytokines and acute phase proteins were the markers used to 
assess the inflammatory response. The rise in the level of these markers is non specific 
and increase in both infective and non infective foci. The half life of these markers is 
very low thus making it not suitable for clinical conditions. Also it is not possible to 
assess the severity of the inflammation and after any therapeutic intervention these 
markers take longer period to reach the baseline. 
 To overcome this in 1990s Procalcitonin was first described as infection induced 
protein detectable in the plasma of patients who present with sepsis.
16
 The marker was 
more specific to the bacterial infections and will not rise if the inflammation was due to 
viral infection. PCT usually remain low if the infection doesn’t lead to inflammatory 
response. 
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Induction and synthesis of  PCT :  
 
 Procalcitonin belongs to CAPA (Calcitonin gene related peptide amylin 
procalcitonin adrenomedullin) protein family. Calcitonin gene related peptides (CGRP ) 
I, II and procalcitonin belong to this group. CGRP I and the mRNA of calcitonin 
precursor were encoded on CALC- I gene on chromosome 11. All these proteins were 
usually produced in pro – pro form consisting of approximately 100 amino acids to gain 
access to golgi system. These prtotein has two cysteine residues to form di sulphide 
bridge and two protein cleavage sites to form final core protein of 35 amino acid which 
can be amidated. 
 
 PCT mRNA is synthesized by CALC- I gene present on chromosome 11 
exclusively during inflammation and sepsis. Calcitonin is also product of CALC- I gene 
secreted from C cells of thyroid gland in normal individuals. PCT producing cells 
secrete two different types of PCT mRNA responsible for forming PCT – I and PCT – II 
which has differences at eight C- terminal amino acids.  CALC - I gene produce three 
sequence of proteins and after processing there are  nine different proteins. These 
proteins differ not only with mRNA splicing and procession , but also with respect to 
their regulation.  
 
 The protein secreted depends on the types of cells involved, stimulus for cellular 
activation and individual susceptibility of various cell types to these stimuli. In C cells of 
thyroid gland calcitonin produced in the native form and stored in golgi apparatus and 
released according to the hormonal or metabolic stimulus. In the absence of infection the 
activity of CALC-I gene is very minimal with negligible PCT I and II levels. Thus the 
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concentration in the plasma of healthy individuals is 10-50 pg/ml. In humans PCT I and 
PCT II mRNA is found mainly in liver, lung, kidney and testis.
17
 Ex vivo it is possible to 
produce PCT mRNA in immunocompetent cells like mononuclear cells when it is 
stimulated by endotoxin.
18
  
 
 PCT has secondary and tertiary structure that is modified by post translational 
processing. Protein modification occurs by glycosylation. Di peptidyl peptidase enzyme 
located on renal, epithelial and endothelial cells induced by proinflammatory mediators 
and endotoxin and is responsible for deamidation of PCT.
19
 Till now the function of 
biologically active PCT molecule is not known.  
 
 PCT undergo enzymatic cleavage to form N- terminal aminoprocalcitonin 
fragment (N – pro) and the conjoined calcitonin : katacalcin fragment. These fragments 
were present in the plasma of septi patients which can be measured. PCT is also 
synthesized by circulating peripheral monocytes. But this is not the only source. By 
various studies and animal experiments it is concluded that the liver is responsible for 
major secretion of PCT at the time of sepsis and infection.
20
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Procalcitonin  (PCT) :  
 Procalcitonin is a peptide precursor of calcitonin hormone which is secreted 
mainly by the parafollicular C cells of the thyroid gand . Calcitonin is responsible for the 
calcium metabolism and to maintain the calcium homeostasis in the body. PCT  is made 
of 116 amino acids which is also secreted by the neuro endocrine cells of the liver, lung 
and intestine only at the time of inflammatory process. The increased PCT at the time of 
inflammation does not have any role in calcium metabolism. 
 
PROCALCITONIN  - ng/ml 
Normal 0.05 
Local infection < 0.5 
Systemic infection 0.5 - 2 
Sepsis 2 – 10 
Severe Sepsis >10 
 
 The advantage of PCT clinically over other markers is its half life and reactive 
pattern for an inflammatory stimulus. Its half life is 24h and within 4hr of infection PCT 
will start increasing and peaks at 6hr, attain a plateau at 8-24hr and then it takes 2-3 days 
to return to base line. Clinically this will be helpful to repeat the PCT investigation once 
in 3 days.  Regarding other markers like tumor necrosis factor-alpha (TNF- ) having 
90 min onset and return to base line in 6h; interleukin-6 (IL-6) onset of 3hr and comes to 
base line in 8hr and C-reactive protein (CRP) with onset of 12-24 hr with plateau of 20-
72 hrs and return to base line by 3-7 days were having less half life when compare to 
PCT.
21 
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Studies of PCT  in sepsis other than Burns 
 
 PCT has been utilised to differentiate bacterial from viral meningitis in children. 
This will helps in avoiding antibiotics and its adverse effects in meningitis due to viral 
cause.
22
  
 
         PCT is a diagnostic biomarker which can be utilised for the assessment of disease 
severity and will be the guidance for treating bacterial infections. This diagnostic 
biomarker will be a complementary for the clinical diagnoses of the infection. So the cut 
off values  will be based on many diagnostic studies. Biomarker should never be utilised 
alone and always should be considered along with the clinical signs and symptoms of 
infection.
23
  
 
                    PCT used as a diagnostic tool for early indicator of sepsis who present to the 
emergency department. The study was done both in adult and pediatric age group. 
Empirical antibiotics can be started based on PCT level before the documentation of 
bacteria and the response can be assessed with serial PCT level measurement.
24,25
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PCT evaluation related to burns:  
 
 There are studies done in the past related to procalcitonin in burns patient. Most of 
the studies were done for evaluating the parameters like CRP, ESR and WBC. The 
changes in these parameters at the time of burns has been compared to the procalcitonin 
levels and concluded that procalcitonin has higher specificity when the sepsis starts due 
to bacterial origin. Also it is  known that the changes in other markers are not specific  as 
they keep  rising in both hypermetabolic response and sepsis. So it is not possible to 
consider a cut off margin of these markers above which we can consider it as established 
sepsis. 
 
  Normal value of PCT in adult male : 0.05ng/ml. The level of procalcitonin for the 
diagnosis of sepsis  vary in different studies from >0.5 ng/ml to 3ng/ml. Previously one 
of the criteria for diagnosing burns sepsis was leucocyte count, which may be either 
leucocytosis or leucopenia. According to the American burn association these counts are 
very unreliable and thus it has been excluded from the newer definition of burns sepsis.
26
  
 
  A Study done by Barati et al regarding Comparison of WBC, ESR, CRP and PCT 
serum levels in septic and non-septic burn cases concluded that PCT is a highly efficient 
laboratory parameter involving a simple and rapid bedside test for diagnosis and 
prognosis of severe infectious complications after burn.
27
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 A Study done by Athina Lavrentieva et al , evaluated serum PCT, CRP, leukocyte 
count and temperature as markers of sepsis and divided the cases in to two groups as 
sepsis with SIRS and sepsis without SIRS and concluded that PCT is a better marker of 
sepsis than other inflammatory markers and the area under ROC curve has an acceptable 
accuracy.
28
  
 
  Another study done by D. von Heimburg et al  Procalcitonin -  a sepsis 
parameter in severe burn injuries, they assessed the PCT values and compared with the 
Baltimore sepsis score (BSS). There was a significant correlation between the BSS and 
rise in PCT level. A PCT value of 10ng/ml and increasing suggestive of severe systemic 
infection even when the blood culture was negative. A cut off value of 3ng/ml and above 
suggestive of bacterial infection and less than this patients will have better prognosis.
29
  
 
  In contrary to all these there are some studies which has shown the 
negative implications on PCT level compared to other markers. Like the study done by 
L. Bargues et al , Evaluation of serum procalcitonin concentration in the ICU following 
severe burn concluded that PCT does not offer a significant advantages for diagnosis of 
sepsis in burns, compared with the other biological markers such as C-reactive protein 
(CRP) and white blood count (WBC). In their study CRP has more sensitive and specific 
in diagnosing the burns sepsis.
30
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Statistical Analysis 
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The following statistical analysis were used: 
 
1) Fisher exact test for categorical data. 
2) ROC curve to assess the diagnostic performance. 
3) t test  
4) Mann whitney U test to know the significance. 
 
To analyse the data SPSS software was used. 
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Results and analysis 
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RESULTS AND ANALYSIS:  
 
 Data of 36 patients were analysed with mean age of 27.97 yr (2-59 yr). Among 
them 44% were male, 42% female and 14% children sustained burns of > 20% TBSA. 
The average total body surface area of burns was 47.16 (20 – 97 %). Majority of the 
patients, 86% (31) sustained thermal burns and remaining 14% (05) had electrical burns. 
Out of 18 patients five patients (27.77%) had lung infection, 08 (44.44%) patients had 
positive growth of organism in blood culture and 05 (27.77%)patients had local wound 
sepsis with  growth of multiple organisms. The organisms grown in blood culture was 
Pseudomonas in 3 patients, Klebsiella in 2, Acinetobacter  in 01, MRSA in  2. 
 
  
 The diagnostic validity was maximum at the cut off value of 5ng/ml which gives 
sensitivity – 88.9% and specificity of 83.3% with positive predictive value of 84.2%. To 
test the significance of PCT in sepsis and non sepsis patients Mann whitney U test was 
applied and the p – value of < 0.0001 suggest the significant association of PCT in 
assessing the sepsis. All patients who died had increase in PCT value without any drop. 
So serial measurement of the PCT has more prognostic value. The cut off value of PCT 
<5 ng/ml  indicates localized infection. If the level started increasing >5ng/ml without 
any drop one should strongly suspect sepsis in presence of other clinical parameters. All 
the patients who had MODS (Multi Organ Dysfunction Syndrome) due to uncontrolled 
sepsis or failure in treatment  had PCT levels of >10 ng/ml and increasing further. 
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DEMOGRAPHIC PROFILE 
 
Age distribution :  Fifteen patients  (41.66% ) were in the age group of 21-30yrs with 
mean age of 27.97 
 
TABLE : 1 
 
 
 
Spearmans rank correlation coefficient did not reveal any relationship between age and 
PCT values. 
 
 
 
 
 
 
Age
0 - 10 yrs
11-20 yrs
21-30 yrs
31-40 yrs
41-50 yrs
51-60 yrs
n=36
04
05
15
06
04
02
Percentage
11.11
13.88
41.66
16.66
11.11
5.55
36 
 
DISTRIBUTION OF SEX : 
 
Total of 36 cases 16(44%) were male, 15(42%) were female and 05(14%) were children. 
TABLE : 2 
 Patients  Percentage 
MALE 16 44 
FEMALE 15 42 
CHILDREN 05 14 
TOTAL 36 100 
 
 
Fig: 1 
 
 
Analysis with Mann whitney U test did not reveal any significant relationship between 
distribution of sex and rise in PCT level. 
44%
42%
14%
Distribution of sex
Male Female Child
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Mode of injury 
Majority of the patients sustained thermal burns (86%) followed by electrical burns 
(13.9%). 
 
TABLE : 3 
 
 
Fig: 2 
 
 
 
86%
14%
Mode of injury
Thermal Electrical
 
Number of patients Percentage 
Electrical  05 13.8 
Thermal  31 86.2 
Total  36  
38 
 
 
 
PERCENTAGE OF BURNS 
 
Twenty seven percent had burns within 30% of Total body surface area. There was no 
correlation between the percentage of burns and PCT values though higher values were 
noted in early phase of electrical injuries. 
 
TABLE : 4 
 
 
 
  
 
 
 
 
% TBSA of 
burns
21-30
31-40
41-50
51-60
61-70
71-80
81-90
91-100
n=36
10
04
08
07
03
01
02
01
Percentage
27.77
11.11
22.22
19.44
8.33
2.77
5.55
2.77
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Development of sepsis in study group: 
TABLE : 5 
 
  
Number  of patients 
 
Percentage 
 
With sepsis 
 
18 
 
50 
 
Without sepsis 
 
18 
 
50 
 
Total 
 
36 
 
 
 
Half of the cases 18 (50%) fulfil the criteria for sepsis. 
Fig: 3 
 
 
 
With sepsis
50%
Without sepsis
50%
sepsis 
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Finding cut off value of Procalcitonin using ROC Curve 
 
 
 
 
Fig 4, Receiver operating characteristic curve (ROC) showing the diagnostic performance 
of PCT in sepsis.  (Y axis – Sensitivity, X  axis – 1- Specificity). 
For each PCT value plotted on ROC curve sensitivity and specificity is calculated. The 
value which is plotted most nearer to the 1 is the cut off value (5ng/ml). Two 
perpendicular lines were drawn to join X and Y axis which shows sensitivity and 1-
specificity to that value. 
Sensitivity – 88.9% , Specificity – 83.3%. 
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Co-ordinates of the curve : 
 
TABLE : 6 
 
PCT cut off value Sensitivity  1 - specificity 
3.812 0.889                     0.222 
4.903 (=5) 0.889                     0.167 
5.729 0.833                     0.167 
 
 
 The predictive ability of the PCT was determined by using the ROC(Receiver 
operating curve) and the area under the curve was calculated with 95% confidence 
intervals. Analysis of the coordinate points reveled the best threshold values of PCT for 
the prediction of sepsis based on the combination of sensitivity and specificity of each 
proposed threshold. The cut off value was 5ng/ml based on the ROC analysis with area 
under the curve of 91%. 
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Procalcitonin and sepsis – Testing the significance of association 
TABLE : 7 
 
 
 
 
 
 
 
 
 
 
 
 
With sepsis (n = 18) Without sepsis (n=18) 
Mean  43.30 3.5 
Median  39.92 1.99 
Std deviation 26.65 4.03 
Min PCT value 3.25 0.1025 
Max PCT value 125 15.30 
                              25  31.06 0.89 
Percentile             50 39.92 1.99 
                              75 49.69 5.10 
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Mann Whitney U test 
 
TABLE 8 
 
 
Analysis with Mann Whitney U test for the relationship between Procalcitonin and 
sepsis revealed significant correlation (p value < 0.0001) . 
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Diagnostic performance of PCT in sepsis : 
 
TABLE : 9 
 
Variables  
sepsis 
Cut off value (ng/ml)   5 
Sensitivity (%) 88.9 
Specificity (%) 83.3 
PPV  (%) 84.2 
NPV  (%) 88.2 
AUC 0.917 
ROC significance 0.0001 
95% CI                                 Lower 0.825 
                                               Upper 1.000 
 
 
 
PPV – Positive predictive value, NPV – Negative predictive value,CI – Confidence 
interval , ROC – Receiver operating characteristic curve,  AUC – Area under ROC,  
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Discussion    
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Discussion :   
 
How sepsis in burns differ from the sepsis due to other causes ? 
  
           
 
Fig : 6 : Relationship between infection , SIRS and sepsis. 
 
  
 
 
 
 
 
 
 
47 
 
 One of the most common cause of sepsis in general population is  infection. The 
cause of infection may be bacterial , viral or fungal. The development of sepsis follows 
sequence of events. Any infection localized or systemic if not treated leads to 
development of SIRS. The criteria to define SIRS were mentioned earlier and is due to 
activation of various inflammatory mediators. SIRS is basically a normal physiologic 
response of the human body towards a noxious stimulus. If the causative agent is not 
removed this will cause more exaggerated SIRS and ultimately leads to development of 
sepsis , severe sepsis and end up with MODS (Multi Organ Dysfunction Syndrome) 
followed by death as shown in Fig 2. 
 
 
 Though the infection is the primary cause for SIRS this is not always true. 
There are some conditions where SIRS occur in absence of infection e.g. major 
trauma, pancreatitis, burns etc. These are the conditions in which body respond to 
the injury initially by means of SIRS in absence of infection. The severity of the 
SIRS depends on the initial injury. In cases with major burns the SIRS is invariably 
followed by infection of the skin. In burns patients SIRS starts initially due to the 
direct thermal injury to the skin and in later stage it is due to repeated insults caused 
by infection. So in major burns patients after the resuscitation period it is always 
difficult to differentiate whether SIRS is a result of injury itself or due to 
superimposed infection.  
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Fig : 7 The events following untreated infection 
 
 Routinely diagnoses of sepsis in burns were based on clinical and biochemical 
factors as explained by the American Burns Association (ABA – 2007). Due to the 
presence of chronic inflammatory state in burns, the criteria explained by ABA to 
diagnosis sepsis is either overlooked or under looked. Clinically it is very important 
to identify systemic infection at the earliest of its stage to initiate antibiotic therapy 
and to prevent further sepsis . Though blood culture is the gold standard to diagnose 
systemic infection it will take several days to get the growth of infecting organism 
and also the presence of negative culture doesn’t assure the absence of infection. So 
it is necessary to identify the indirect circulating markers of systemic infection that 
can be rapidly assessed and reliable. Many markers were mentioned which is 
discussed below in briefly.  
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Markers which are used as sepsis indicators: 
 
1) C- reactive protein  
2) Cytokines 
3) Adrenomedullin 
4) Atrial natriuretic peptide 
5) Protein C 
6) Endocan 
7) Neopterin 
 
C- reactive protein : 
 
 In response to infection or inflammation there is an acute phase response in the 
body which causes change in concentration of many plasma proteins. A plasma protein 
to designate as acute phase protein its concentration should increase or decrease at least 
by 25% during inflammatory disorders.
31
 C- reactive protein is one of them and the 
concentration increase by 1000 fold at the time of inflammation. Though the CRP rise at 
the time of infection or sepsis there are drawbacks to consider it as a potent 
inflammatory marker. Because  CRP doesn’t indicate the severity of sepsis, as it 
increases even in minor infections , doesn’t correlate with the severity of host response, 
its values doesn’t differ between survivors and non survivors of sepsis. The increase in 
concentration at the time of sepsis is not much helpful for the clinical diagnosis as it 
reaches its peak not before 48hrs after onset of infection and also present in the plasma 
for a prolonged period even after control of sepsis.
32
 CRP is not specific for sepsis as it 
also rises in some of the non infectious conditions like rheumatic disorders, acute 
50 
 
coronary syndromes, malignancy and after surgery.
33
 But one of the promising role of 
CRP is in assessing the antibiotic response when used to treat localized infections. 
 
Cytokines :  
 
 Any inflammatory insult cytokines were the primary mediators. These are 
glycoproteins which are released by macrophages, monocytes, lymphocytes, and 
endothelial cells. Efforts were made to assess the level of cytokines which can reflect the 
severity of the inflammation. Tumor necrosis factor-a, IL-1, IL-6, IL-8, and IL-10 are 
the important cytokines which are considered to assess the sepsis. Among these IL-6 and 
IL-8 increase by 1000 fold and suppose to be a marker of sepsis.
34
 But the major 
drawback in clinical use is its very short half life of few minutes  and the circulating 
levels falls when it binds with the receptor antagonist. 
 
Adrenomedullin:  
 
 The major functions of this molecule is it acts as autocrine, paracrine and 
endocrine mediators in many biologically significant mechanisms. It helps in  protection 
of organs during sepsis, it has antimicrobial properties against Gram positive and Gram 
negative organisms. It has role in modulating the complement cascade. This molecule 
has been considered to play a major role in hyperdynamic state of septic shock. The 
levels of adrenomedullin correlate well with the sepsis severity score and helps in 
predicting the septic shock.
35
 As the half life of this molecule is about 22 min and it has 
a binding protein it is very difficult practically to consider in a clinical scenario. 
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Atrial natriuretic peptides:  
 
 This secreted by the distension of atria caused by myocardial depression. This 
plays an important role in regulation of fluid volume. This may become a potential 
marker but need further evaluation.
36
  
 
Protein C:   
 
 This is one of the important molecule in coagulation cascade. The concentration of 
protein c decrease many folds about 12 hrs before the onset of septic shock.
37
 It has also 
been documented that infusion of protein c helps in decreasing 28 day mortality in 
patients with severe sepsis. In association with prothrombin time, antithrombin activity, 
and D-dimer which causes worsening of the coagulation cascade on the first day of 
severe sepsis helps in predicting the organ failure. 
 
Endocan : 
 
  It is produced when endothelial injury occur which is caused at the time of organ 
failure and shock in sepsis. It is also called endothelial cell-specific molecule-1 secreted 
by endothelial cells of lung and kidney at the time of infection in response to 
cytokines.
38
 This helps in regulating cell adhesion in inflammatory disorders and tumour 
progression. This marker is more sensitive and specific for organ failure so helps in 
differentiate from patients having only sepsis. 
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Neopterin:  
 
 it is released from monocytes after stimulated by interferon. It function is 
associated with the cytotoxic reactivity of activated macrophages.  It is not clinically 
valuable as marker as the specificity is less between infectious and non infectious causes 
of sepsis
39
 and also long time of induction and accumulation in patients with renal 
failure. 
 
Thus to define an ideal sepsis marker: 
1) It should add to the clinical findings to confirm the diagnosis. 
2) It should be able to increase several folds at the earlier stage of the sepsis. 
3) The change in its concentration should able to assess the severity of the sepsis 
4) It should reflect the response to the treatment 
5) It shoud be specific for the infection/sepsis due to bacterial origin. 
6) It should differentiate the infectious from non infectious causes. 
7) The half life of the marker should be suitable to repeat at regular intervals which 
are suitable for clinical condition. 
 
 So the ideal sepsis marker doesn’t exist but which can be more reliable than other 
markers is the Procalcitonin. 
 
 PCT is a 13 kd peptite with a conc of <0.1 ng/ml in healthy individual. Normally 
secreted by C cell of thyroid gland but at the time of inflammation it is secreted by 
extrathyroidal tissue liver, lung, kidney, adipocytes and muscle. PCT is used to 
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differentiate infection from bacterial to non bacterial origin. This was proved by many 
studies in the past like to differentiate between bacterial from viral meningitis, bacterial 
pneumonia, fever of unknown origin to rule out etiology of bacterial infection and to rule 
out sterile v/s infected necrosis secondary to acute pancreatitis. There were various cut 
off values for each study and sensitivity and specificity were calculated. PCT will also  
rise in non infective cases as cardiogenic shock, burns, early post operative period, 
polytrauma, heat shock, severe systemic inflammation e.g., secondary to multiple organ 
dysfunction syndrome (MODS). 
  
 Also the levels of PCT is based on severity of the inflammation with less in SIRS 
and increased levels at the terminal stages of septic shock.
40
 The values of PCT correlate 
with the SOFA (Sepsis-related organ failure assessment)  score
41
 and APACHE II 
(Acute physiology and chronic health evaluation II) score
42
 which are the scores of 
severity of organ dysfunction. The kinetics of PCT is suitable for the clinical assessment. 
With an half life of 25-30 hr , PCT will start rising 4hr after the infection or injury, peaks 
at 6hr, attain a plateau for 8-24hrs and will come to base line after 2- 3 days. Serial PCT 
measurement and the course of PCT over time indicate the disease activity and the 
prognosis of systemic inflammation respectively. Continuously increasing PCT has more 
value than the single reading suggestive of disease severity or failure of therapeutic 
measures. 
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ALGORITHM OF THE STUDY PLAN 
 
Fig : 8 
 
 
 
 
 
 
 
 
Step 1
• Cases included in the study 
Step 2
• Monitor daily for the diagnoses of sepsis according 
to American Burn Association sepsis guidelines
Step 3
• Collection of sample for PCT level at the time of 
admission, sepsis and after recovers from sepsis.
Step 4
• Data analysis
Step 5
• Conclusion
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Summary : 
 This was a prospective study done for a period of 9 months to assess the diagnostic 
validity of procalcitonin (PCT) in sepsis patients due to burns. The criteria given by the 
American burn association (ABA) for sepsis in burns were used as reference standard. 
Most of the time in the presence of chronic inflammatory stage the diagnoses of sepsis 
based on ABA criteria was underestimated and delayed in starting the antibiotic which 
may lead to mortality of the patient or overlooked the sepsis condition and started 
antibiotics when it was actually not necessary. This may result in development of 
resistant organisms. To over come this we need a marker which can reflect the infection 
status and also add to the diagnostic criteria of sepsis. Various markers had been 
explained in the past but the PCT was more specific to the infection due to bacterial 
cause. 
 
 A total of 36 patients were included in the study who had burns of > 20%. The 
vital parameters and necessary investigations which fulfill the criteria of sepsis was done 
regularly. To know the diagnostic validity we estimated the baseline PCT level at the 
time of admission or when the patient doesn’t have sepsis. When the patient was 
diagnosed as sepsis one more estimation was done. Data of PCT was collected at the 
time of sepsis and without sepsis were analysed. 
 
 The diagnostic validity of the test, Sensitivity = 88.9%, Specificity= 83.3%, 
Positive predictive value = 84.2% was calculated. The Sensitivity and specificity was 
maximum in our study at the cut off value of PCT at 5ng/ml. So patient will have more 
chances of sepsis with PCT more than 5ng/ml and less when it is <5ng/ml. More than a 
single estimation serial measurement of PCT has more prognostic value. 
57 
 
 
 The etiology of sepsis in burns patients were local wound sepsis, blood stream 
infection, urinary infection and respiratory infection. The PCT value in our study was 
below 5ng/ml when the infection was localized. If the patient was immunologically 
stable and responded to the antibiotics the PCT level was below 5ng/ml. The onset of 
sepsis should be suspected when the PCT level started increasing and the level more 
than 10ng/ml was always had a higher mortality rate which suggests the worsening of 
sepsis which may led to MODS. The initial PCT level in patients sustained high voltage 
electrical burns was higher due to trauma and not because of infection. 
 So the cut off value of PCT mentioned to diagnose sepsis due to other causes is 
less when compared to burns sepsis patients. This may due to persistent SIRS and 
localized infection of burn wound which may increase the basal PCT levels. So in case 
of burns the cut off value to diagnose sepsis is higher than the sepsis due to other causes. 
 
 
 
 
 
 
 
 
 
 
 
 
58 
 
 
 
 
 
 
 
 
 
 
 
Conclusion   
59 
 
Conclusion :  
1) PCT has  high diagnostic validity to  diagnose sepsis in burns patients 
 Sensitivity – 88.9%,       Specificity – 83.3%. 
2) In burns patients the cut off value of PCT to diagnose sepsis is 5 ng/ml. 
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Annexure 1 : proforma and consent form: 
 
CONSENT FORM 
Patient information sheet 
 
  All patients presenting with more than or equal to 20% of burns admitting in 
the burns ward included in the study. The physical and vital parameter changes that occur 
during sepsis in burns patient will be very marginal as most of the patients are in 
hypermetabolic response to the injury. The Procalcitonin (PCT)  levels rise from the 
initial level is one of the early parameter in assessing the sepsis in burns patient. We are 
doing base line PCT level at the time of admission when the patient is free of sepsis. 
Patient will be monitored continuously for any signs and symptoms of sepsis after 
admission. Once the patient fulfils the criteria for sepsis then we are repeating the PCT 
level. Hence PCT level assessed twice, at the time of sepsis and without sepsis. Thus each 
case will serve his/her own control. Collected data will be dividing in to two groups, i.e : 
values noted at the time of sepsis and without sepsis. Those of the patients without an 
episode of sepsis will have a single PCT assay at admission which will serve as a 
baseline/normal PCT estimation reading. In some cases, patient may have a sepsis 
episode more than once and we would do PCT check on each episode of sepsis. At the 
end of the study data will be analysed statistically to find the diagnostic validity of 
Procalcitonin in burns sepsis patients. 
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Please read the details carefully and clarify your queries if any before deciding on 
consenting for the study.  
What is this study about? 
 Study about assessing the diagnostic validity in detecting the sepsis in burns patient. 
Does participating in the study alter the treatment of the patient? 
 No. The patient shall be given the same treatment as planned irrespective of your decision 
to agree or disagree to participate in the study.  
Does doing this investigation  have any side effects? 
 No 
What investigation will be done if I consent for the study? 
 After taking consent a routine blood sample will be taken from the patient to assess the 
level of Procalcitonin at the time admission, sepsis and post sepsis period. 
Will I get compensation if I suffer damage due to the study? 
 You are not likely to have any damage because of the study.  
What do I have to do? 
 You are asked to read this consent form in detail, clarify your doubts if any and sign at 
the end of the form if you decide to participate in the study. 
What will I have to do if I participate in the study? 
 You will have to allow to collect a blood sample of about 3 ml for each test during the 
time of admission for an average of about 2-3 samples and have to respond to the follow-
up calls as and when required. 
Can I say NO to the study? 
 Your participation in the study is completely voluntary and you can choose to either enter 
the study or not to. Your decision will not alter your treatment in the hospital. 
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Will my treatment details be kept confidential? 
 Your personal and medical records will be kept confidential and shall be used only for 
academic and research purposes and may be presented or published in academic circles. 
However, you will not be identified personally. 
Can I withdraw from the study once I consent? 
 Yes. You can opt out of the study if you want. However, your medical records shall be 
available for the academic review even if you discontinue the participation. 
Can my participation in the study be cancelled by the investigators? 
 Yes.  Your participation in the study can be rejected or cancelled without your permission 
or information at any stage during the study period if the investigators wish so for any 
reason.  
 
If you have any more queries, please contact Dr.Naveen Kumar H R    PHONE: 
04162282017      CELL PHONE: 91 9626156754. 
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Informed Consent form to participate in clinical trial 
Study Title: Prospective analysis of Procalcitonin (PCT) in burns sepsis patients 
Subject’s Name: 
Age: 
 (Subject) 
(i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am 
Free to withdraw at any time, without giving any reason, without my medical care or legal 
rights being affected. [ ] 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, 
the Ethics Committee and the regulatory authorities will not need my permission to look 
at my health records both in respect of the current study and any further research that may 
be conducted in relation to it, even if I withdraw from the trial. I agree to this access. 
However, I understand that my identity will not be revealed in any information released 
to third parties or published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided such 
a use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. [ ] 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
Signature of the Investigator: ________________________ 
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Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
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STUDY : Prospective analysis of Procalcitonin (PCT) in burns sepsis patients . 
 
NAME :  
AGE : 
HOSPITAL NO :  
ADDRESS : 
 
 
 
DIAGNOSIS : 
 
TBSA OF BURNS : 
 
DOA :  
 
DOD/DOE : 
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DATA COLLECTING SHEET : 
 
 
 
 
DAY  
 
PROCALCITONIN 
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CULTURE REPORT SHEET :  
 
 
  
 
DAY 
 
 
BLOOD CULTURE/URINE CULTURE/SPUTUM CULTURE/PATHOLOGICAL TISSUE 
  
ORGANISM 
 
SENSITIVITY 
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Annexure 2 : Master Chart 
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MASTER CHART 
 
Hosp no Age Sex Date of burns Date of admission Percentage of burns Diagnosis Pct 1st sample Pct 2nd sample Pct 3rd sample 
028192f 25 F 9/11/2012 11-sep-12 27 Thermal 0.2982 
  
013401f 35 M 9/3/2012 4-sep-12 22 Electrical 0.1025 
  
064524f 59 F 10/5/2012 7-oct-12 61 Thermal 0.3951 7.969 
 
064523f 55 F 11/5/2012 7-nov-12 58 Thermal 0.5045 
  
615516d 49 M 12-may-12 12-may-12 50 Thermal 3.564 8.274 
 
739071d 31 F 7/17/2012 7/17/2012 54 Thermal 0.244 4.374 
 
162377c 47 M 8/31/2012 8/31/2012 44 Thermal 1.698 5.432 
 
089472f 48 M 10/28/2012 4-nov-12 30 Thermal 2.1541 
  
098769f 30 F 11/23/2012 24-nov-12 33 Thermal 1.6441 
  
244196d 23 M 3/1/2012 2-mar-12 21 Electrical 1.0261 
  
133413f 24 F 3/21/2012 22-mar-12 50 Thermal 3.0531 10.5 
 
956996a 20 F 3/16/2012 16-mar-12 66 Thermal 6.8111 41.34 
 
174371f 22 F 5-apr-12 5-apr-12 70 Thermal 3.2511 
  
188435f 9 M 4/28/2012 29-apr-12 60 Thermal 7.289 
  
207329f 29 F 5/19/2012 20-may-12 90 Thermal 10.110 125.000 
 
218428f 29 M 6/4/2012 5-jun-12 20 Thermal 3.147 0.523 
 
936807 35 M 6/11/2012 11-jun-12 27 Thermal 15.770 6.026 1.937 
888851d  49 M 3/11/2012 11-mar-12 55 Electrical 65.600 46.620 
 
558485c 13 F 7/21/2012 22-jul-12 25 Thermal 1.172 1.120 
 
777334d 2 M 8/6/2012 7-aug-12 25 Thermal 2.400 
  
265407f 34 M 7/29/2012 8-aug-12 82 Thermal 33.440 7.587 
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261273f 9 M 7/8/2012 1-aug-12 50 Thermal 1.840 0.307 
 
239446f 21 M 7/4/2012 5-jul-12 50 Electrical 43.130 0.694 
 
064053f 40 M 10/27/2012 10/27/2012 58 Thermal 2.398 10.276 
 
631005d 32 M 8/24/2012 8/24/2012 78 Thermal 1.964 26.512 
 
299400f 30 F 9/17/2012 9/17/2012 50 Thermal 7.791 15.300 
 
309392f 22 F 9/23/2012 28-sep-12 40 Thermal 5.893 1.351 31.930 
299612f 19 M 8/30/2012 14-sep-12 25 Electrical 0.270 
  
347792f 25 M 11/22/2012 22-nov-12 25 Thermal 18.330 42.430 17.970 
338769f 17 F 11/5/2012 11/5/2012 35 Thermal 7.674 9.432 1.318 
341968f 5 M 11/11/2012 20-nov-12 40 Thermal 2.939 
  
338364f 26 M 11/4/2012 11/4/2012 45 Thermal 1.155 0.216 
 
857543d 22 F 3/16/2012 16-mar-12 60 Thermal 3.267 69.014 
 
898831d 25 F 3/12/2012 12-mar-12 46 Thermal 2.643 34.349 67.854 
895555d 28 M 3/7/2012 8-mar-12 56 Thermal 3.568 15.495 41.312 
963010d 18 F 6/13/2012 6/13/2012 97 Thermal 4.156 10.289 
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